Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 25, 2026, 11:36 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 45 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Osteoarthritis of the Knee or Hip Clear all
Completed Phase 3 Interventional Results available

Long-Term Safety and Efficacy Study of Fasinumab in Patients With Pain Due to Osteoarthritis (OA) of the Knee or Hip

NCT02683239
View directory record Official record
Conditions
Osteoarthritis of the Knee or Hip
Interventions
Fasinumab, Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
5,331 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
50
States / cities
Birmingham, Alabama • Chandler, Arizona • Glendale, Arizona + 44 more
Source: ClinicalTrials.gov public record
Updated Oct 12, 2023 · Synced Jul 25, 2026, 11:36 AM EDT
Completed Phase 3 Interventional Results available

Study of Meloxicam Capsules to Treat Osteoarthritis Pain

NCT01787188
View directory record Official record
Conditions
Osteoarthritis
Interventions
Meloxicam Test Capsules, Placebo Capsules
Drug
Lead sponsor
Iroko Pharmaceuticals, LLC
Industry
Eligibility
40 Years and older
Enrollment
403 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
40
States / cities
Birmingham, Alabama • Carmichael, California • Pismo Beach, California + 31 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2015 · Synced Jul 25, 2026, 11:36 AM EDT
Completed No phase listed Observational

Understanding the Differences in the Management of Patients With Arthritis of the Knee or Hip

NCT00105677
View directory record Official record
Conditions
Osteoarthritis, Arthritis, Degenerative, Osteoarthritis, Hip, Osteoarthritis, Knee
Interventions
Not listed
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
50 Years to 79 Years
Enrollment
980 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Pittsburgh, Arizona
Source: ClinicalTrials.gov public record
Updated Apr 6, 2015 · Synced Jul 25, 2026, 11:36 AM EDT
Completed Phase 3 Interventional

Study of Efficacy, Safety of Fulranumab Monotherapy for OA of Hip or Knee, PAI3003

NCT02289716
View directory record Official record
Conditions
Osteoarthritis, Pain
Interventions
Placebo, Fulranumab 1 mg, Fulranumab 3 mg
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 99 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
7
States / cities
El Cajon, California • Sherman Oaks, California • Miami, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2025 · Synced Jul 25, 2026, 11:36 AM EDT
Completed Phase 3 Interventional Results available

Tanezumab in Osteoarthritis of the Hip or Knee (2)

NCT00863304
View directory record Official record
Conditions
Osteoarthritis
Interventions
tanezumab 10 mg, tanezumab 5 mg, naproxen, placebo
Biological · Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
849 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
95
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 69 more
Source: ClinicalTrials.gov public record
Updated May 16, 2021 · Synced Jul 25, 2026, 11:36 AM EDT
Completed Phase 3 Interventional

Study of Efficacy, Safety of Fulranumab Adjunctive Use in OA of Hip or Knee, PAI3001

NCT02336685
View directory record Official record
Conditions
Osteoarthritis, Pain
Interventions
Placebo, Fulranumab 1 mg, Fulranumab 3 mg, Opioid
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 99 Years
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
36
States / cities
Birmingham, Alabama • Huntsville, Alabama • Cerritos, California + 33 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2017 · Synced Jul 25, 2026, 11:36 AM EDT
Terminated Phase 3 Interventional Results available

Tanezumab In Osteoarthritis Of The Hip Or Knee

NCT00985621
View directory record Official record
Conditions
Osteoarthritis
Interventions
tanezumab 10 mg, tanezumab 5 mg, oxycodone, placebo
Biological · Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
614 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
66
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 54 more
Source: ClinicalTrials.gov public record
Updated May 13, 2021 · Synced Jul 25, 2026, 11:36 AM EDT
Completed Phase 3 Interventional

A Study Comparing the Effectiveness and Safety of Varying Dose Strengths (100, 200, 300 and 400 mg) of Extended-release Tramadol HCl With Placebo for the Treatment of Osteoarthritis(OA) of the Knee and/or Hip

NCT00325858
View directory record Official record
Conditions
Chronic Pain
Interventions
Tramadol HCl ER
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years to 74 Years
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
1
States / cities
Duncansville, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 26, 2012 · Synced Jul 25, 2026, 11:36 AM EDT
Completed Phase 2 Interventional

A Study of the Safety and Effectiveness of Orally Administered CR845 in Patients With Osteoarthritis of the Hip or Knee

NCT02524197
View directory record Official record
Conditions
Osteoarthritis
Interventions
CR845 0.25 mg, CR845 0.50 mg, CR845 1 mg, CR845 5 mg
Drug
Lead sponsor
Cara Therapeutics, Inc.
Industry
Eligibility
25 Years and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
5
States / cities
Omaha, Nebraska • Las Vegas, Nevada • Greensboro, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2017 · Synced Jul 25, 2026, 11:36 AM EDT
Terminated Phase 3 Interventional Results available

Long-Term Study Of The Safety Of Tanezumab In Arthritis Patients

NCT00960804
View directory record Official record
Conditions
Osteoarthritis
Interventions
Tanezumab, Placebo
Biological · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 99 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
18
States / cities
Atlantis, Florida • Fort Myers, Florida • South Miami, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 7, 2021 · Synced Jul 25, 2026, 11:36 AM EDT
Completed Phase 3 Interventional Results available

A Study of Embeda (Kadian NT, ALO-01) in Subjects With Pain Due to Osteoarthritis of the Hip or Knee

NCT00420992
View directory record Official record
Conditions
Osteoarthritis, Chronic Pain
Interventions
ALO-01 (Morphine Sulfate Plus Naltrexone Hydrochloride Extended Release), Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
21 Years and older
Enrollment
547 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
81
States / cities
Birmingham, Alabama • Mobile, Alabama • Peoria, Arizona + 69 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2013 · Synced Jul 25, 2026, 11:36 AM EDT
Completed Phase 3 Interventional

A Study of Pain Relief in Osteoarthritis

NCT00298974
View directory record Official record
Conditions
Osteoarthritis
Interventions
hydrocodone / acetaminophen extended release, Placebo
Drug
Lead sponsor
Abbott
Industry
Eligibility
21 Years to 80 Years
Enrollment
873 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
83
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 68 more
Source: ClinicalTrials.gov public record
Updated Jan 24, 2011 · Synced Jul 25, 2026, 11:36 AM EDT
Completed Not applicable Interventional Results available

Shoe Lifts for Leg Length Inequality in Adults With Knee or Hip Symptoms

NCT01894100
View directory record Official record
Conditions
Leg Length Inequality, Osteoarthritis, Knee, Osteoarthritis, Hip
Interventions
Shoe lift correction for leg length inequality
Device
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
55 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Smithfield, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 13, 2017 · Synced Jul 25, 2026, 11:36 AM EDT
Active, not recruiting Not applicable Interventional

Conversations in Health Literacy Using AI Technology for Osteoarthritis Patients

NCT06778486
View directory record Official record
Conditions
Osteoarthritis, Osteoarthritis of the Hip or Knee
Interventions
Artificial Intelligence Chatbot
Other
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years to 99 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Jul 25, 2026, 11:36 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Buprenorphine Transdermal System in Subjects With Moderate to Severe Osteoarthritis of Hip or Knee

NCT00313846
View directory record Official record
Conditions
Osteoarthritis
Interventions
Buprenorphine transdermal patch, Placebo
Drug
Lead sponsor
Purdue Pharma LP
Industry
Eligibility
40 Years to 75 Years
Enrollment
529 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
44
States / cities
Mesa, Arizona • Phoenix, Arizona • Tucson, Arizona + 38 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2012 · Synced Jul 25, 2026, 11:36 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Pain Expectations in Subjects With Osteoarthritis

NCT02155257
View directory record Official record
Conditions
Osteoarthritis
Interventions
Modafinil, Gabapentin, Placebo
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 6, 2019 · Synced Jul 25, 2026, 11:36 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Incorporating Patient-Reported Outcomes Into Shared Decision Making With Patients With Osteoarthritis of the Hip or Knee

NCT04805554
View directory record Official record
Conditions
Osteo Arthritis Knee
Interventions
Joint Insights decision aid
Other
Lead sponsor
University of Texas at Austin
Other
Eligibility
45 Years to 89 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jan 4, 2024 · Synced Jul 25, 2026, 11:36 AM EDT
Completed Phase 3 Interventional

A Multi-Center Actual-Use Study on the Safety of CL 108 for the Treatment of Moderate to Severe Acute Pain Associated With Osteoarthritis of the Knee or Hip

NCT02462850
View directory record Official record
Conditions
Pain, Nausea, Vomiting
Interventions
CL-108
Drug
Lead sponsor
Charleston Laboratories, Inc
Industry
Eligibility
18 Years and older
Enrollment
178 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Jul 25, 2026, 11:36 AM EDT
Terminated Phase 3 Interventional Results available

Evaluate the Efficacy and Safety of Fasinumab in Patients With Moderate-to-Severe Chronic Low Back Pain and Osteoarthritis of the Hip or Knee

NCT03285646
View directory record Official record
Conditions
Chronic Low Back Pain, Osteoarthritis
Interventions
Fasinumab, Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
56
States / cities
Phoenix, Arizona • Tucson, Arizona • Anaheim, California + 47 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2021 · Synced Jul 25, 2026, 11:36 AM EDT
Terminated Phase 3 Interventional Results available

Extension Study Of Tanezumab In Osteoarthritis

NCT00809783
View directory record Official record
Conditions
Osteoarthritis
Interventions
tanezumab
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 99 Years
Enrollment
2,147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
226
States / cities
Anniston, Alabama • Birmingham, Alabama • Huntsville, Alabama + 148 more
Source: ClinicalTrials.gov public record
Updated May 9, 2021 · Synced Jul 25, 2026, 11:36 AM EDT
Completed Phase 3 Interventional Results available

Study of Diclofenac Capsules to Treat Osteoarthritis Pain

NCT01461369
View directory record Official record
Conditions
Osteoarthritis
Interventions
Diclofenac, Placebo
Drug
Lead sponsor
Iroko Pharmaceuticals, LLC
Industry
Eligibility
40 Years and older
Enrollment
305 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
40
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Anaheim, California + 31 more
Source: ClinicalTrials.gov public record
Updated May 25, 2014 · Synced Jul 25, 2026, 11:36 AM EDT
Completed Phase 3 Interventional Results available

A Study to Determine the Safety and the Efficacy of Fasinumab Compared to Placebo and Naproxen for Treatment of Adults With Pain From Osteoarthritis of the Knee or Hip

NCT03161093
View directory record Official record
Conditions
Osteoarthritis, Knee, Osteoarthritis, Hip
Interventions
Fasinumab, Naproxen, Fasinumab-matching placebo, Naproxen-matching placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
3,307 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
58
States / cities
Mesa, Arizona • Phoenix, Arizona • Tucson, Arizona + 50 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2022 · Synced Jul 25, 2026, 11:36 AM EDT
Completed Phase 3 Interventional Results available

Study of Meloxicam Capsules in Subjects With Osteoarthritis of the Knee or Hip

NCT01801735
View directory record Official record
Conditions
Osteoarthritis
Interventions
Meloxicam Test Capsules
Drug
Lead sponsor
Iroko Pharmaceuticals, LLC
Industry
Eligibility
40 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
40
States / cities
Birmingham, Alabama • Phoenix, Arizona • Carmichael, California + 32 more
Source: ClinicalTrials.gov public record
Updated May 11, 2015 · Synced Jul 25, 2026, 11:36 AM EDT
Completed Phase 3 Interventional Results available

Open-Label Study of Diclofenac Capsules to Treat Osteoarthritis Pain

NCT01510912
View directory record Official record
Conditions
Osteoarthritis
Interventions
Diclofenac
Drug
Lead sponsor
Iroko Pharmaceuticals, LLC
Industry
Eligibility
40 Years and older
Enrollment
602 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
40
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Anaheim, California + 31 more
Source: ClinicalTrials.gov public record
Updated May 8, 2014 · Synced Jul 25, 2026, 11:36 AM EDT